在囊性纤维化患者中发现的655种CFTR变异的体外调节器响应性
Hermann Bihler1, Andrey Sivachenko1, Linda Millen2
1CFFT Lab, Cystic Fibrosis Foundation, Lexington, MA 02421, USA.
概括
这项研究确定了新的囊性纤维化跨膜导电性调节器 (CFTR) 基因变异,这些变异对elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) 治疗有反应. 这些发现扩大了CF (pwCF) 和罕见CFTR变异患者的治疗资格.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 美国FDA扩大了囊性纤维化 (CF) 治疗的药物标签,包括CFTR基因变异.
- 目前的CFTR调节器疗法基于基因变异具有特定的合格标准.
- 识别响应的CFTR变异对于扩大CF (pwCF) 患者的治疗机会至关重要.
研究的目的:
- 通过elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) 处理,识别出具有增强化物 (Cl-) 运输功能的CFTR变异.
- 评估ELX/TEZ/IVA对广泛的CFTR变异的功能影响.
- 提供可能将调节器治疗资格扩展到更多pwCF的数据.
主要方法:
- 感染过的费舍尔鼠甲状腺细胞具有655个CFTR变异和野生类型 (WT) CFTR.
- 在用ELX/TEZ/IVA进行化后,使用体电流管导电性试验评估CFTR功能.
- 测量了基线和药物反应的Cl-运输活性,并通过西方斑点评估了CFTR蛋白质成熟.
主要成果:
- 253个未经批准的CFTR变异显示出低基线活性 (<10%的正常值).
- 在这些变体中的152种中,ELX/TEZ/IVA治疗改善了Cl-传输≥10%,这表明了潜在的临床益处.
- 另有140种未经批准的变种,具有10-50%的基线功能,在ELX/TEZ/IVA中显示了≥10个百分点的功能增加.
结论:
- 这项研究显著扩大了可能对ELX/TEZ/IVA反应的罕见CFTR变异的数量.
- 研究结果表明,ELX/TEZ/IVA可能为更广泛的pwCF群体提供临床益处.
- 这项研究通过详细介绍对调节器的变异特异性反应,支持在CF治疗中个性化医疗方法.
更多相关视频
09:59Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein
Published on: March 9, 2015
12.2K
08:00Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
10.7K
相关概念视频
01:23Cystic Fibrosis: Pathogenesis
241
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
241
01:24Cystic Fibrosis: Management
164
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
164